Integral Molecular
Integral Molecular is a privately held Philadelphia biotechnology company developing proprietary membrane protein technologies and therapeutic antibody discovery platforms. It serves 600+ pharmaceutical and biotechnology customers including all Top 20 pharma with fee-for-service research, reagents, and therapeutic licensing.
- Company typePrivate
- Founded2001
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Integral Molecular does
Integral Molecular is a privately held biotechnology company founded in 2001 by University of Pennsylvania scientists and headquartered in Philadelphia, Pennsylvania. The company specializes in membrane protein research and therapeutic antibody discovery, operating a portfolio of proprietary technology platforms including the Membrane Proteome Array (MPA) for specificity testing against 6,000+ human membrane proteins, Lipoparticle virus-like particle technology for presenting conformationally intact membrane proteins, the MPS Antibody Discovery Platform using divergent (chicken) immunization against challenging targets such as GPCRs and ion channels, Shotgun Mutagenesis Epitope Mapping at single amino acid resolution, Paratope-PLUS CDR-Scanning for genus-level patent enablement, and Reporter Virus Particles for safe viral neutralization assays.
The company generates revenue through four streams: fee-for-service contract research (specificity testing, antibody discovery, epitope mapping), reagent and product sales (Lipoparticles, virology reagents), therapeutic asset licensing (programs including CLDN6 licensed to Context Therapeutics, CLDN18.2 licensed to Cartexell, and undisclosed oncology targets licensed to AstraZeneca), and success-based pricing for Target Identification projects. It serves more than 600 customers and partners including all Top 20 pharmaceutical companies, with named clients spanning AstraZeneca, Pfizer, Merck, Novartis, Boehringer Ingelheim, Ono Pharmaceutical, Merus, Sutro Biopharma, and Cabaletta Bio. MPA specificity data has been accepted in over 100 IND filings by the FDA, EMA, and NMPA.
The company distributes services through direct enterprise sales with scientific consultation and maintains a global distributor network for virology reagents (Scientist.com, KRISHGEN Bio Systems, Sung Woo, Funakoshi) plus a dedicated e-commerce platform. Operations are based at a 50,000 sq. ft. facility at One uCity Square in Philadelphia, with the regional workforce expanded to 200+ following a 2023 $1M Commonwealth of Pennsylvania grant. The company has been profitable since inception and has operated primarily on approximately $21 million in non-dilutive NIH and state grants over its 25-year history, remaining founder-owned and led by President and CEO Benjamin Doranz (PhD, MBA).
Integral Molecular firmographics
Firmographics- Name
- Integral Molecular
- Legal name
- Integral Molecular
- Website
- https://integralmolecular.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Integral Molecular is a privately held Philadelphia biotechnology company developing proprietary membrane protein technologies and therapeutic antibody discovery platforms. It serves 600+ pharmaceutical and biotechnology customers including all Top 20 pharma with fee-for-service research, reagents, and therapeutic licensing.
- Ownership category
- akta.pro rank
Integral Molecular industry classification
Industry- Product category
- Antibody Discovery and Characterization Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Integral Molecular is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Integral Molecular business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Fee-for-Service Contract Research: Project-based fee-for-service arrangements for antibody discovery, specificity testing, epitope mapping, and other技术服务. Customers pay for specific research services with defined deliverables.
- Reagent and Product Sales: Sale of virology reagents including Reporter Virus Particles, ReadyReceptor Lipoparticles, and custom reagent products. Products available through direct ordering and distributor network.
- Therapeutic Asset Licensing: Licensing of proprietary therapeutic antibody assets discovered using MPS platform. Includes CLDN6, CLDN18.2, GPRC5D, CCR8, P2X3, and P2X7 programs. Licensing models range from straight-out licensing to joint research collaborations.
- Success-Based Pricing: Target Identification services offered with success-based pricing structure where customers pay lower fees if screening does not identify validated targets, protecting customer investment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Standard MPA Specificity Testing - 8-week turnaround |
| Other | Pay-as-you-go | MPA+IND Regulatory Submission Service - 4-week turnaround |
| Outcome Based/ Performance | Pay-as-you-go | Target Identification Projects - 8-10 week turnaround |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Integral Molecular product offering
Product offeringCore offering
Integral Molecular provides cell-based antibody specificity testing services using its Membrane Proteome Array (MPA) platform that screens biotherapeutics against 6,000+ human membrane proteins in unfixed cells. The company also offers therapeutic antibody discovery using the MPS platform with Lipoparticle and chicken immunization technology, high-resolution Shotgun Mutagenesis epitope mapping, Paratope-PLUS CDR-Scanning for antibody IP protection, and a portfolio of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays.
Product overview
Integral Molecular is a biotechnology company offering a portfolio of technology platforms and services for membrane protein research and antibody therapeutics discovery. The core products include the Membrane Proteome Array™ (MPA) for antibody specificity testing against 6,000+ membrane proteins, the MPS Antibody Discovery Platform for generating therapeutic antibodies against challenging targets like GPCRs and ion channels, and Lipoparticles™ (virus-like particles) for presenting membrane proteins in native conformation. Supporting platforms include Shotgun Mutagenesis Epitope Mapping for high-resolution antibody epitope characterization, Paratope-PLUS® CDR-Scanning for antibody IP protection and engineering, and a suite of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays. The company also offers specialized services including Target Identification using the MPA platform, MPA+IND for regulatory submissions, and Enhanced Binding Analysis for follow-up studies.
Differentiator
Problem solved
Functional benefit
Brands
- Membrane Proteome Array (MPA): Cell-based protein array for antibody specificity testing against 6,000+ human membrane proteins
- MPS Antibody Discovery Platform
- Lipoparticle Technology
- Shotgun Mutagenesis Epitope Mapping
- Paratope-PLUS CDR-Scanning
- Ready Reporter Virus (RRV) Kits
Products and services
- Membrane Proteome Array (MPA) Cell-based protein array service that screens antibodies, CAR-T cells, ADCs, and other biotherapeutics against approximately 6,000 human membrane proteins (94% of the human membrane proteome) using unfixed cells and quantitative flow cytometry to identify off-target binding for pharmaceutical and biotech customers.
- Shotgun Mutagenesis Epitope Mapping High-throughput service mapping conformational epitopes at single amino acid resolution using alanine-scanning mutation libraries expressed in live human cells, without requiring purified proteins. Over 1,500 epitopes mapped with >95% success rate.
- Paratope-PLUS CDR-Scanning Site saturation mutagenesis service testing every possible amino acid substitution at each CDR residue to support antibody engineering and patent protection by identifying all permissible substitutions that retain or improve binding.
- Lipoparticles (Virus-Like Particles) Non-infectious virus-like particles containing high concentrations of conformationally intact membrane proteins at 10-100x cell concentration, used for antibody immunization and screening against GPCRs, ion channels, transporters, and immuno-oncology targets.
- MPS Antibody Discovery Platform Therapeutic antibody discovery service specifically designed for challenging membrane protein targets including GPCRs, ion channels, and transporters. Uses Lipoparticle, RNA, and DNA antigens with chickens as divergent immunization hosts to deliver diverse panels of humanized monoclonal antibodies with >95% success rate.
- Reporter Virus Particles (RVPs) Non-replicative pseudotyped viral particles used as BSL-2 safe alternatives to live virus for infectivity and neutralization assays across influenza, SARS-CoV-2, dengue, Zika, Chikungunya, Ebola, Marburg, and Nipah viruses. Trusted by 100+ laboratories.
- Ready Reporter Virus Kit Thaw-and-use neutralization assay kit that delivers results in under 4 hours using non-replicative virus particles displaying native viral proteins for safe and rapid virus neutralization testing.
- Influenza TiterSafe Particles Ready-to-use influenza reagent designed for easier hemagglutination inhibition (HAI) assays used by vaccine developers and serology laboratories.
- Neutralization Assay Services Fee-for-service neutralization testing for antibody developers requiring neutralization data on their candidates.
- Target Identification Services Uses the Membrane Proteome Array to identify unknown targets of antibodies, serum samples, or recombinant proteins. Also known as target deconvolution, antibody deorphaning, or target discovery. Success-based pricing available.
- ReadyMap Libraries Pre-constructed, pre-validated epitope mapping libraries updated regularly with new targets to enable faster turnaround and lower cost shotgun mutagenesis epitope mapping projects.
Quantifiable outcome
- 1 in 3 antibody drug candidates demonstrate off-target binding, making specificity testing essential for patient safety
- +5 more outcomes
Companies that use Integral Molecular
Customer profileNamed customers17 records
Segments5 records
Ideal customer profiles3 records
Integral Molecular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
Integral Molecular partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MeruscoreStrategic partnership and license agreement for novel therapeutic monoclonal antibodies. Merus stated that Integral Molecular's capabilities complement their ability to advance their therapeutic pipeline dedicated to delivering novel antibody therapeutics to patients.
- Ono PharmaceuticalcoreAntibody discovery collaboration. Ono Pharmaceutical stated they were impressed by Integral Molecular's membrane protein expertise and proven record in discovering antibodies against membrane proteins.
- Scientist.comminorOnline marketplace distributor for virology reagents. Enables researchers to discover and purchase Integral Molecular products through Scientist.com's procurement platform.
- KRISHGEN Bio SystemsminorRegional distributor for Korean market offering Integral Molecular virology reagents and products.
- Sung WoominorRegional distributor for Korean market offering Integral Molecular virology reagents and products.
- FunakoshiminorRegional distributor for Japanese market offering Integral Molecular virology reagents and products.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Integral Molecular competitors and assessment
Company assessmentDirect peers
- Retrogenix (Charles River Laboratories): Retrogenix offers a cell-based protein microarray for antibody and protein specificity screening against human membrane proteins, the most direct competitor to Integral Molecular's Membrane Proteome Array. It was acquired by Charles River Laboratories, giving it significant commercial reach.
- AbCellera Biologics: AbCellera operates a single-cell antibody discovery platform partnering with pharma to develop therapeutic antibodies. Comparable in serving large pharma with antibody discovery services and licensing programs, though its discovery engine is single-cell sequencing rather than membrane-protein focused.
- Adimab: Adimab is a private antibody discovery and engineering platform serving pharma and biotech partners. Directly comparable in providing fee-for-service and partnered therapeutic antibody discovery with a mature CRO-style business model.
- Antibody Solutions: Antibody Solutions is a focused antibody discovery CRO offering custom monoclonal antibody generation services. Comparable as a smaller-scale specialty CRO targeting therapeutic antibody discovery for biotech and pharma clients.
Broad incumbents
- Charles River Laboratories: Charles River is a large CRO offering discovery, safety assessment, and biologics services. Comparable as a partner of choice for pharma antibody programs, with the Retrogenix acquisition putting it in direct competition with Integral Molecular's specificity testing offering.
- WuXi Biologics: WuXi Biologics is a global biologics CRO/CDMO providing antibody discovery, cell line development, and manufacturing services. Comparable as an enterprise-scale service provider for pharma antibody pipelines, with broader scope than Integral Molecular.
- Eurofins Scientific: Eurofins is a global bioanalytical testing services group with extensive capabilities in pharmacology, ADME, and immunology. Comparable as a large-scale CRO partner for biopharma safety and specificity testing requirements.
- GenScript ProBio: GenScript offers antibody discovery, protein production, and biologics CDMO services. Comparable in providing fee-for-service antibody discovery and protein engineering services to pharma and academic customers.
- Crown Bioscience: Crown Bioscience is a CRO providing preclinical and translational services for oncology and immuno-oncology drug development. Comparable in offering fee-for-service research supporting therapeutic antibody development pipelines of pharmaceutical sponsors.
Emerging players
- Alloy Therapeutics: Alloy Therapeutics operates a distributed antibody discovery platform with ATX-Gx transgenic mice, complementing Integral Molecular's chicken-based discovery. The companies are also technology partners, indicating overlap in antibody discovery infrastructure for biotech.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key highlights7 records
Customer concentration
Integral Molecular social profiles
Digital presenceIntegral Molecular compliance and trust
Trust signalCompliance1 record
Integral Molecular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integral Molecular leadership team
Management profileNumber of profiles
Profiles11 records
Integral Molecular funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integral Molecular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integral Molecular
What does Integral Molecular do?
Integral Molecular provides cell-based antibody specificity testing services using its Membrane Proteome Array (MPA) platform that screens biotherapeutics against 6,000+ human membrane proteins in unfixed cells. The company also offers therapeutic antibody discovery using the MPS platform with Lipoparticle and chicken immunization technology, high-resolution Shotgun Mutagenesis epitope mapping, Paratope-PLUS CDR-Scanning for antibody IP protection, and a portfolio of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays.
Is Integral Molecular a public or private company?
Integral Molecular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Integral Molecular founded?
Integral Molecular was founded in 2001. It employs 11 to 50 people.
Where is Integral Molecular based?
Integral Molecular is headquartered in Philadelphia, United States, in the North America region.
How does Integral Molecular make money?
Four revenue lines are on record. Fee-for-Service Contract Research is the primary driver. The others are reagent and Product Sales, therapeutic Asset Licensing and success-Based Pricing.
Who are Integral Molecular's main competitors?
Direct peers on record are Retrogenix (Charles River Laboratories), AbCellera Biologics, Adimab and Antibody Solutions. Broad incumbents are Charles River Laboratories, WuXi Biologics, Eurofins Scientific, GenScript ProBio and Crown Bioscience. Alloy Therapeutics is listed as an emerging player.
Does Integral Molecular have an API?
No public API is recorded for Integral Molecular.
What industry is Integral Molecular in?
Integral Molecular's product category is Antibody Discovery and Characterization Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325413 and its SIC code is 2834.